BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity

BioCryst's Orladeyo revenue rose 6.7% quarter over quarter to $158.2 million in Q2, while royalty-financing obligations fell by $38.9 million to $426.8 million at the end of June from $465.7 million at Q4 2025. Despite improving product revenue and lower financing obligations, the company’s shares remain under pressure, producing a mixed near-term investment signal.